首页 | 本学科首页   官方微博 | 高级检索  
     


Doxorubicin- and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy
Authors:Huifeng Di  Haiyan Wu  Ying Gao  Weihua Li  Dongna Zou
Affiliation:1. Department of Pharmacy, Laiwu City People’s Hospital, Laiwu, China;2. Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong University, Ji’nan, China
Abstract:Context: Combination anticancer therapy is promising to generate synergistic anticancer effects, to maximize the treatment effect and to overcome multi-drug resistance. Nanostructured lipid carriers (NLCs), composed of solid and liquid lipids, and surfactants are potentially good colloidal drug carriers.

Objective: The aim of this study is to construct novel NLCs as nanocarriers for co-delivery of doxorubicin (DOX) and cisplatin (CDDP) to treat breast cancer.

Methods: DOX and CDDP loaded NLCs (D–C-NLCs) were prepared by the solvent diffusion method. The in vitro cytotoxicity and synergistic studies of different formulations were evaluated on human breast cancer cells (doxorubicin resistant) (MCF-7/ADR cells). In vivo anti-tumor effects were observed on the murine bearing MCF-7/ADR cells model.

Results: D–C-NLCs showed the highest cytotoxicity and synergistic effect of two drugs in tumor cells in vitro. The in vivo study revealed the greatest anti-tumor activity than the other formulations in the breast cancer model.

Conclusion: The constructed NLCs could be used as a novel carrier for co-delivery of DOX and CDDP for breast cancer therapy. D–C-NLCs could be a promising targeted and combinational therapy nanomedicine.

Keywords:Breast cancer  co-delivery system  combination chemotherapy  multi-drug resistance  nanostructured lipid carriers
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号